Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Case Report

PBS. 2015; 5(2): 78-82

Ketamine infusion in treatment resistant depression: a case report and brief review of the literature

Gökben Hızlı Sayar, Eylem Özten, Haluk A. Savaş.

The glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may exhibit antidepressant effect. Previous studies of treatment-resistant depression reveal that ketamine infusions may result in a rapid antidepressant response with improvement usually sustained for several days. This case suggests that intravenous administration of ketamine may be effective for immediate relief from symptoms in unipolar depression and may also relieve suicidal ideation. Due to the prolonged period between the initiation of treatment and the onset of action of currently available antidepressants, only a few things can be done for the management of acute and severe suicidal ideation other than close monitoring or hospitalization. Rapid effect of ketamine may be an advantage in the management of suicide risk. Although additional research is needed to ascertain optimal dosing schedules and route of administration of ketamine, NMDA agents warrant further investigation as a treatment option in treatment-resistant depression and as an agent intended to reduce suicides.

Key words: depression, ketamine, suicide, treatment resistance

Share this Article

Journal of Apitherapy


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.